César Gómez

Cardiology fellow 🫀

[Davide Capodanno @DFCapodanno]

This State-of-the-Art review provides a comprehensive and practical overview of coronary interventions related to TAVI, encompassing coronary evaluation and physiological assessment, the indications and timing of percutaneous coronary intervention before and after valve implantation, and strategies for managing coronary obstruction. https://t.co/yojhLj5N5p

[César Gómez @CesGoRo]

@ArgaizR @Hilda2787 @NephroP @nephrothaniel Muchas felicidades amigo

[Carlo Tumscitz @skat_ct]

A Little trick to save the radial access for an arterial line after #PCI, thanks to @GianlucaCampo78 for the idea!

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Hi Everyone -

🥸Here are all the 27 late breaking clinical trials presented at @ACCinTouch (ACC.26) with session number, day, time, and objective.

😱See you in NOLA:

👇👇👇

[Dr. Chokri Ben Lamine @abouabdrahman0]

Credits for sharing to Dr. Abdulrahman Nassiri 💐👌🤝

100 concise pearls from the 2026 AHA/ACC Guideline for Acute PE

🫀 Acute PE – 100 Pearls

1️⃣ PE risk stratification is mandatory before therapy.
2️⃣ New AHA/ACC Acute PE Clinical Categories A–E introduced.
3️⃣ Category A = incidental, asymptomatic PE.
4️⃣ Category B = symptomatic, low severity score.
5️⃣ Category C = elevated severity score ± RV strain.
6️⃣ Category D = incipient cardiopulmonary failure.
7️⃣ Category E = cardiopulmonary failure.
8️⃣ Use validated clinical probability tools.
9️⃣ Wells score remains practical.
🔟 Revised Geneva score validated.

1️⃣1️⃣ PERC rule avoids unnecessary imaging in very low-risk.
1️⃣2️⃣ Always assess pretest probability before imaging.
1️⃣3️⃣ Age-adjusted D-dimer recommended.
1️⃣4️⃣ Threshold = age ×10 μg/L (FEU).
1️⃣5️⃣ <2% failure acceptable for PE exclusion.
1️⃣6️⃣ YEARS algorithm reduces imaging burden.
1️⃣7️⃣ D-dimer strategies unsafe if already anticoagulated.
1️⃣8️⃣ Pregnancy-adapted YEARS supported.
1️⃣9️⃣ Avoid over-testing in low probability patients.
2️⃣0️⃣ CTPA is first-line imaging.

2️⃣1️⃣ Positive CTPA confirms PE.
2️⃣2️⃣ High-probability V/Q is diagnostic.
2️⃣3️⃣ Prefer CTPA over planar V/Q.
2️⃣4️⃣ V/Q SPECT better than planar V/Q.
2️⃣5️⃣ Echo cannot rule in or rule out PE.
2️⃣6️⃣ RV/LV ratio should be reported numerically.
2️⃣7️⃣ RV/LV ≥1 suggests RV strain.
2️⃣8️⃣ TAPSE <1.6 cm abnormal.
2️⃣9️⃣ McConnell’s sign indicates RV dysfunction.
3️⃣0️⃣ Report chronic thromboembolic signs on CT.

3️⃣1️⃣ LMWH preferred over UFH initially.
3️⃣2️⃣ DOACs preferred over VKAs.
3️⃣3️⃣ DOACs reduce major bleeding.
3️⃣4️⃣ Extended anticoagulation if unprovoked PE.
3️⃣5️⃣ Treat first episode ≥3–6 months minimum.
3️⃣6️⃣ Persistent risk → continue beyond 6 months.
3️⃣7️⃣ Evaluate bleeding risk regularly.
3️⃣8️⃣ IVC filters not routine.
3️⃣9️⃣ Use IVC filter only if anticoagulation contraindicated.
4️⃣0️⃣ Remove IVC filter when safe.

4️⃣1️⃣ Category A patients can be discharged.
4️⃣2️⃣ Category B often early discharge.
4️⃣3️⃣ Category C requires hospitalization.
4️⃣4️⃣ Category D needs close monitoring.
4️⃣5️⃣ Category E needs aggressive intervention.
4️⃣6️⃣ Persistent hypotension defines high risk.
4️⃣7️⃣ Use biomarkers for risk stratification.
4️⃣8️⃣ Troponin elevation signals myocardial injury.
4️⃣9️⃣ BNP elevation suggests RV strain.
5️⃣0️⃣ PE Response Teams (PERT) recommended.

5️⃣1️⃣ Systemic thrombolysis for high-risk PE.
5️⃣2️⃣ Consider advanced therapy in D1–D2.
5️⃣3️⃣ Catheter-directed thrombolysis reasonable.
5️⃣4️⃣ Mechanical thrombectomy evolving option.
5️⃣5️⃣ Surgical embolectomy when indicated.
5️⃣6️⃣ ECMO for refractory shock.
5️⃣7️⃣ Avoid routine thrombolysis in low-risk PE.
5️⃣8️⃣ Evaluate for contraindications before lytics.
5️⃣9️⃣ Monitor for intracranial hemorrhage risk.
6️⃣0️⃣ Early recognition saves mortality.

6️⃣1️⃣ Assess hemodynamics continuously.
6️⃣2️⃣ Monitor oxygenation closely.
6️⃣3️⃣ HFNC or NIV may be required.
6️⃣4️⃣ Mechanical ventilation cautiously.
6️⃣5️⃣ Avoid aggressive fluid overload.
6️⃣6️⃣ Use vasopressors if hypotension.
6️⃣7��⃣ Norepinephrine preferred.
6️⃣8️⃣ Reassess category over time.
6️⃣9️⃣ Clinical status can evolve rapidly.
7️⃣0️⃣ Repeat imaging only if clinically indicated.

7️⃣1️⃣ Ask about dyspnea at every follow-up visit.
7️⃣2️⃣ Screen for CTEPD at least 1 year.
7️⃣3️⃣ Persistent symptoms need evaluation.
7️⃣4️⃣ Chronic RV strain needs specialist input.
7️⃣5️⃣ Exercise intolerance must be addressed.
7️⃣6️⃣ Educate patients about recurrence risk.
7️⃣7️⃣ Travel guidance important.
7️⃣8️⃣ Activity resumption individualized.
7️⃣9️⃣ Avoid routine thrombophilia testing acutely.
8️⃣0️⃣ APS alters anticoagulation choice.

8️⃣1️⃣ Cancer-associated PE requires special planning.
8️⃣2️⃣ Pregnancy PE requires low-dose protocols.
8️⃣3️⃣ Avoid over-radiation in pregnancy.
8️⃣4️⃣ Avoid under-treatment of high-risk PE.
8️⃣5️⃣ Document RV strain in report.
8️⃣6️⃣ Quantify clot burden cautiously.
8️⃣7️⃣ Clot burden alone not treatment determinant.
8️⃣8️⃣ Clinical severity score essential.
8️⃣9️⃣ Hemodynamics trump imaging.
9️⃣0️⃣ Biomarkers add prognostic

[Marwan Jumean, MD @JumeanMarwan]

From #pressor support to #impella support in #cardiogenicshock—how stable #pMCS enables #prehabilitation in the #ICU Gym and changes the trajectory. 💪

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Coronary revascularization: a long-term perspective: @ESC_Journals

🥸 Great paper...

😱 Summary

👇👇👇

[Dr. Joshuan J. Barboza @joshuanbarbozam]

Si quieres aprender investigación clínica, estas son lecturas obligatorias 🔍📚⁣
Fuentes de alto nivel, claras y prácticas para desarrollar criterio científico.
✅ NEJM – Clinical Trials Series
https://t.co/INxrdhIkUl
Explicaciones esenciales sobre el diseño, análisis e interpretación de ensayos clínicos. 🧪
✅ JAMA Evidence
https://t.co/oT98i46srG
Conceptos clave de MBE, guías clínicas y herramientas para entender la evidencia. 📖✨
✅ JCLEPI – Key Concepts in Clinical Epidemiology
https://t.co/y5hcAIHve0
Fundamentos de epidemiología clínica explicados con claridad. 📊
✅ JCLEPI – GRADE Guidance
https://t.co/Xm9bzZfnrY
Todo lo necesario para entender y aplicar el sistema GRADE. 🎯
Formación rigurosa, fuentes confiables y lectura imprescindible para fortalecer tu práctica clínica. 💡👨‍⚕️👩‍⚕️
Dr. Joshuan J. Barboza
@joshuanj_barboza

[Dr. FEVI🫀🩺 @javier20ch]

⚠️Escenarios clínicos donde los ACOD no deben indicarse. ✍️🏻🚫💊
🔶️Los ACOD (apixabán, rivaroxabán, dabigatrán y edoxabán) han reemplazado en gran medida a los AVK (warfarina, acenocumarol) para la FA y la TVP/TEP, gracias a su eficacia similar y menor riesgo de sangrado intracraneal. Sin embargo, hay escenarios clínicos donde los ACOD no deben considerarse estándar por menor eficacia o mayor riesgo: 🧐⤵️
📛Válvulas cardíacas mecánicas: ensayo RE-ALIGN (dabigatrán) y PROACT-Xa (apixabán) mostraron mas eventos trombóticos y hemorragicos.
📛FA reumática (estenosis mitral): ensayo INVICTUS (rivaroxabán), mayor mortalidad y eventos embólicos con ACOD.
📛Sx Antifosfolípido trombótico: riesgo de ACV 10 veces mayor con ACOD.
📛Post-TAVI: ensayos GALILEO, ATLANTIS, ENVISAGE-TAVI-AF, sin beneficio o mayor sangrado con ACOD.
📛Embolia cerebral de origen indeterminado (ESUS): ensayos NAVIGATE-ESUS y RE-SPECT-ESUS, sin beneficio sobre aspirina y mayor sangrado.
📛Dispositivo de asistencia ventricular izquierda: mayor trombosis con dabigatrán.
🚩Áreas inciertas⁉️➡️ trombo en VI post-IAM, trombosis asociada a catéter venoso, trombosis de seno venoso cerebral o esplácnica, pacientes con ERC terminal.

📚🆓️⤵️
https://t.co/MnKhpzuIuf
https://t.co/HzLlpONiop

[Ahmed Ata @Ahmedata7777]

Prosthetic Aortic Valve Stenosis Echo assessment

https://t.co/KPMNeiVFVs

[Ankur Kalra @AnkurKalraMD]

In two consecutive @JACCJournals papers, we systematically describe the characteristics of hemorrhagic ST-segment elevation myocardial infarction patients in the U.S., and the cardioprotective role of collateral circulation in intramyocardial hemorrhage. #JACCAdv @CandiceSilvers1 https://t.co/Y0OFL6tyKn

[Pablo Corral MD @drpablocorral]

👉Managing Dyslipidemia in 2025: The Era of Precision Lipidology

☝️As we move through 2025, dyslipidemia management has clearly evolved beyond the traditional statin + ezetimibe approach.

☝️We now have an expanding armamentarium of targeted therapies addressing triglyceride-rich lipoproteins, LDL-C, and Lp(a) — each with distinct mechanisms and indications.

☝️Emerging agents — including siRNA-based therapies for ApoCIII and ANGPTL3, monoclonal antibodies like evinacumab, oral PCSK9 inhibitors, and even gene editing tools like CRISPR-Cas9 — are reshaping how we stratify and treat high-risk patients.

☝️These therapies are not experimental anymore — they are becoming part of routine cardiovascular risk reduction strategies in selected populations.

@society_eas

[The Heart @ZHeart11768530]

🔴Alteplase (tPA): Indications and dosage in various medical emergencies⤵️

🔹The dose in ischemic stroke is
0.9mg per kg
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX #cardiovascular

[El Hamriti Mustapha @melhamriti]

👇Fascicular VT (Part 1): Basic ECG Findings👇

•Left Posterior Fascicular VT: ECG pattern shows RBBB (right bundle branch block) and LAFB (left anterior fascicular block).
•Left Anterior Fascicular VT: ECG pattern shows RBBB (right bundle branch block) and LPFB (left posterior fascicular block).

👉 A very beautifully video 🤩🤩 created by @N_Trajkovska 👍💪

@Phiso_de @chris_sohns @MBraunEP @MoneebKhalaph @Cardioschool @VanessaSciacca_ @StephanWinnik @YoungDgk @AGEP_DGK #EPeeps #CardioTwitter @jjmt_ep @BSCCardiology @AbbottNews @ECGEPSCADEVICE @Ecgloverr @ChristianHeeger @EPWaveDoc

[Robert Herman, MD, PhD @RobertHermanMD]

New #EKG patterns in acute myocardial infarction due to thrombotic plaque rupture:
❌ STEMI / NSTEMI
✅ State of the coronary artery

Great work by @fabrizioricci @martini_chia!

[Eduardo R Argaiz @ArgaizR]

A small but relevant contribution!

#VExUS in pre-Capillary pulmonary hypertension

https://t.co/zpO1XmEkpl

Congratulations to first author @SergioAlday11 and the #VExUS team @tumleal and @CesGoRo

[Nick Mark MD @nickmmark]

🧂Hyponatremia is a common the ICU, but correcting it smoothly &amp; safely can be challenging.

🧠Rapid correction risks serious complications like ODS/CPM

📈That's why I built NaPathway - a free app - to help clinicians monitor sodium correction

Try it https://t.co/nE8tFI5d0k
🧵

[Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) @Basalus]

Let’s talk about the Top 10 cardiology papers of 2024 that shook up the field!
Hard science, no BS, 🚀 and yes — some practices WILL change.
🫀 Let’s dive in: a tweetorial thread!
#CardioTwitter #MedEd #Cardiology

[César Gómez @CesGoRo]

“An incredibly interesting and educational case with outstanding images! 👏👏 Huge thanks to the amazing team!”

[Mario AJ Leal-Villarreal @tumleal]

🚨Multimodality imaging of aortic root prosthesis dehiscence in prosthetic valve endocarditis🚨

Don’t miss our interesting “Image Focus” case
https://t.co/oMz6RQx6yU

#EHJDigital

[César Gómez @CesGoRo]

😯